Grace Therapeutics, Inc. (GRCE) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2025. Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) is a clinical-stage biopharmaceutical company focused on developing novel drug delivery technologies for rare and orphan diseases. The company is currently prioritizing the development and regulatory review of its lead candidate, GTx-104, an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH). Other candidates, GTx-102 and GTx-101, have been deprioritized pending additional funding or partnerships.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2025 | Nine Months Ended Dec 31, 2025 | Cash Position (Dec 31, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | Cash & Equivalents: $18,672 |
| Net Loss | $(2,315) | $(6,615) | Total Assets: $68,488 |
| Loss Per Share (Basic/Diluted) | $(0.14) | $(0.41) | Total Liabilities: $3,596 |
| Operating Expenses | $(2,449) | $(8,067) | Share Count: 15,474,026 |
| Operating Cash Flow | N/A | $(7,174) | Runway: >12 months |
Note: The company has no revenue and incurs losses primarily from research and development (R&D) and general and administrative (G&A) expenses.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by $1,840 (three months) and $3,589 (nine months) compared to the prior year periods. This improvement was driven primarily by a significant reduction in R&D expenses following the completion of the pivotal Phase 3 STRIVE-ON trial for GTx-104 in February 2025.
- R&D Expenses: R&D expenses dropped from $2,194 to $462 (three months) and from $7,877 to $1,985 (nine months) year-over-year.
- G&A Expenses: G&A expenses increased slightly, rising from $1,510 to $1,987 (three months) due to pre-commercial planning costs for GTx-104.
- Derivative Warrant Liability: The company settled its derivative warrant liability of $241 in October 2025 following the expiration of 2023 Common Warrants. Consequently, there is no remaining derivative warrant liability as of December 31, 2025.
- Capital Raises: In February 2025, the company completed a private placement netting $13,705. In October 2025, it received $4,040 from the exercise of common warrants.
Guidance, Outlook, and Risks
- Regulatory Milestone: The FDA accepted the New Drug Application (NDA) for GTx-104 on August 22, 2025, with a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026.
- Commercialization: Management is preparing for a potential commercial launch of GTx-104, including building a hospital-based sales force and developing Continuing Medical Education (CME) programs.
- Liquidity: Management believes current cash resources ($18.7 million) are sufficient to fund operations for at least 12 months. However, the company expects to require additional capital to fund daily operations beyond that period and to support commercialization if GTx-104 is approved.
- Risks: Key risks include the uncertainty of FDA approval for GTx-104, the need for additional financing which may be dilutive, and the potential inability to commercialize the product if approval is not granted. The company has no internal manufacturing capabilities and relies on third-party contract manufacturers.
Investor Verification Checklist
- Approval Timeline: Verify the status of the GTx-104 NDA review and the April 23, 2026 PDUFA date.
- Cash Runway: Confirm the sufficiency of the $18.7 million cash balance against projected burn rates for the next 12 months and potential commercialization costs.
- Financing Needs: Assess the likelihood and terms of future capital raises required post-approval or if approval is delayed.
- Warrant Expirations: Note that 2023 Common Warrants expired in October 2025, while 2025 Common Warrants remain outstanding with an exercise price of $3.395.
- Deprioritized Assets: Understand that GTx-102 and GTx-101 development is paused pending funding or partnership opportunities.